oxidopamine has been researched along with Multiple System Atrophy Syndrome in 9 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 5.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "In the present experiment we studied the ability of embryonic striatal grafts to protect against striatal quinolinic acid (QA)-induced excitotoxicity in a previously established double lesion rat model of striatonigral degeneration (SND), the neuropathological substrate of parkinsonism associated with multiple system atrophy (MSA)." | 3.70 | Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). ( Humpel, C; Levivier, M; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Waldner, R; Wenning, GK, 2000) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 1.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "Levodopa-unresponsive parkinsonism is present in 80% of MSA cases, and this dominant clinical presentation (MSA-P) is associated with a combined degeneration of the substantia nigra pars compacta and the striatum in anatomically related areas." | 1.33 | In vivo models of multiple system atrophy. ( Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (88.89) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaindlstorfer, C | 1 |
| García, J | 1 |
| Winkler, C | 2 |
| Wenning, GK | 8 |
| Nikkhah, G | 1 |
| Döbrössy, MD | 1 |
| Mantoan, L | 1 |
| Stefanova, N | 5 |
| Egger, KE | 1 |
| Jellinger, KA | 1 |
| Poewe, W | 6 |
| Scherfler, C | 4 |
| Sather, T | 1 |
| Diguet, E | 2 |
| Puschban, Z | 5 |
| Tison, F | 4 |
| Fernagut, PO | 2 |
| Ghorayeb, I | 3 |
| Petersén, A | 1 |
| Brundin, P | 1 |
| Köllensperger, M | 1 |
| Reindl, M | 1 |
| Waldner, R | 1 |
| Seppi, K | 1 |
| Humpel, C | 1 |
| Levivier, M | 1 |
| Goebel, GP | 1 |
| Jellinger, K | 1 |
| Rouland, R | 1 |
9 other studies available for oxidopamine and Multiple System Atrophy Syndrome
| Article | Year |
|---|---|
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopami | 2012 |
Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Amino Acid Chloromethyl Ketones; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Cas | 2005 |
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat | 2005 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice | 2005 |
Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy.
Topics: Amphetamine; Animals; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Male; | 2005 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Lat | 2007 |
Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Apomorphine; Autoradiography; Binding, Competitive; Brain Tissue Transplantation; Corpus St | 2000 |
Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glial Fibrillary Acidic Protein; Male; Motor Activ | 2000 |
Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Topics: Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Forelimb; Male; Micr | 2001 |